Regeneus has sharpened its focus on its area of expertise in early-stage development of regenerative medicine products and cancer vaccines. This strategy appears to be bearing fruit, with partnering arrangements for both its human and veterinary off-the-shelf stem cell therapies expected to be finalised before the end of CY15. A partnering deal for Progenza in Japan is likely to be a re-rating catalyst. Our valuation is A$106m (A$0.51/share).
09 Sep 2015
Potentially two partnering deals in H215
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Potentially two partnering deals in H215
Regeneus has sharpened its focus on its area of expertise in early-stage development of regenerative medicine products and cancer vaccines. This strategy appears to be bearing fruit, with partnering arrangements for both its human and veterinary off-the-shelf stem cell therapies expected to be finalised before the end of CY15. A partnering deal for Progenza in Japan is likely to be a re-rating catalyst. Our valuation is A$106m (A$0.51/share).